ID :
158660
Tue, 02/01/2011 - 15:15
Auther :
Shortlink :
https://www.oananews.org//node/158660
The shortlink copeid
U.S. venture assigns iPSC patent estate to Kyoto Univ
KYOTO, Feb. 1 Kyodo - U.S. venture iPierian Inc. has assigned its patent estate for induced pluripotent stem cells, or iPSCs, to Kyoto University in a bid to avoid a dispute with Shinya Yamanaka, a professor at the university who has developed iPSC technologies, the university said Tuesday.
The assignment came as the U.S. Patent and Trademark Office was about to examine the iPierian patent estate, similar to Yamanaka's technology estate for which patent applications have been filed in Japan and other countries, including the United States.
The U.S. venture offered to assign the patent estate late last year, hoping to avoid a dispute, the university said.
While no financial payments accompanied the assignment, the university signed a licensing agreement to grant iPierian nonexclusive worldwide rights to the university's iPSC technology patent estate for use in drug discovery and development, it said.
''The most important benefit (of the assignment) is that I can spend more time on research,'' Yamanaka said. ''I would like to cooperate with iPierian in promoting drug discovery and development.''
In 2008, the U.S. venture acquired from Bayer Schering Pharma AG the iPSC patent estate, based on research conducted at the Kobe Research Center of Bayer Yakuhin Ltd. and covering around 30 cases for which patent applications have been filed in various countries.
The assignment came as the U.S. Patent and Trademark Office was about to examine the iPierian patent estate, similar to Yamanaka's technology estate for which patent applications have been filed in Japan and other countries, including the United States.
The U.S. venture offered to assign the patent estate late last year, hoping to avoid a dispute, the university said.
While no financial payments accompanied the assignment, the university signed a licensing agreement to grant iPierian nonexclusive worldwide rights to the university's iPSC technology patent estate for use in drug discovery and development, it said.
''The most important benefit (of the assignment) is that I can spend more time on research,'' Yamanaka said. ''I would like to cooperate with iPierian in promoting drug discovery and development.''
In 2008, the U.S. venture acquired from Bayer Schering Pharma AG the iPSC patent estate, based on research conducted at the Kobe Research Center of Bayer Yakuhin Ltd. and covering around 30 cases for which patent applications have been filed in various countries.
